Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 12th:
Bristol-Myers Squibb Company (BMY - Free Report) : This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.9% over the last 60 days.
Bristol-Myers Squibb Company Price and Consensus
This Zacks Rank #1 (Strong Buy) company has a dividend yield of 3.38%, compared with the industry average of 2.77%. Its five-year average dividend yield is 2.67%.
Bristol-Myers Squibb Company Dividend Yield (TTM)
The AES Corporation (AES - Free Report) : This diversified power generation and utility company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
The AES Corporation Price and Consensus
This Zacks Rank #2 (Buy) company has a dividend yield of 3.51%, compared with the industry average of 2.93%. Its five-year average dividend yield is 3.58%.
The AES Corporation Dividend Yield (TTM)
The Buckle, Inc. (BKE - Free Report) : This retailer of apparel, accessories and footwear has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.6% over the last 60 days.
Buckle, Inc. (The) Price and Consensus
This Zacks Rank #2 (Buy) company has a dividend yield of 4.75%, compared with the industry average of 0.00%. Its five-year average dividend yield is 3.95%.
Buckle, Inc. (The) Dividend Yield (TTM)
Arbor Realty Trust, Inc. (ABR - Free Report) : This real estate investment trust and national direct lender has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.
Arbor Realty Trust Price and Consensus
This Zacks Rank #1 (Strong Buy) company has a dividend yield of 9.08%, compared with the industry average of 4.18%. Its five-year average dividend yield is 8.61%.
Arbor Realty Trust Dividend Yield (TTM)
Find more top income stocks with some of our great premium screens.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 12th:
Bristol-Myers Squibb Company (BMY - Free Report) : This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.9% over the last 60 days.
Bristol-Myers Squibb Company Price and Consensus
This Zacks Rank #1 (Strong Buy) company has a dividend yield of 3.38%, compared with the industry average of 2.77%. Its five-year average dividend yield is 2.67%.
Bristol-Myers Squibb Company Dividend Yield (TTM)
The AES Corporation (AES - Free Report) : This diversified power generation and utility company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.8% over the last 60 days.
The AES Corporation Price and Consensus
This Zacks Rank #2 (Buy) company has a dividend yield of 3.51%, compared with the industry average of 2.93%. Its five-year average dividend yield is 3.58%.
The AES Corporation Dividend Yield (TTM)
The Buckle, Inc. (BKE - Free Report) : This retailer of apparel, accessories and footwear has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.6% over the last 60 days.
Buckle, Inc. (The) Price and Consensus
This Zacks Rank #2 (Buy) company has a dividend yield of 4.75%, compared with the industry average of 0.00%. Its five-year average dividend yield is 3.95%.
Buckle, Inc. (The) Dividend Yield (TTM)
Arbor Realty Trust, Inc. (ABR - Free Report) : This real estate investment trust and national direct lender has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.
Arbor Realty Trust Price and Consensus
This Zacks Rank #1 (Strong Buy) company has a dividend yield of 9.08%, compared with the industry average of 4.18%. Its five-year average dividend yield is 8.61%.
Arbor Realty Trust Dividend Yield (TTM)
Find more top income stocks with some of our great premium screens.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on AES - FREE
Get the latest research report on BKE - FREE
Get the latest research report on ABR - FREE